SWOT Analysis for Oncocyte Corporation

MACD Crossover Above Signal Line
Positive Breakout Second Resistance ( LTP > R2)
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Strong Momentum: Price above short, medium and long term moving averages
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
MACD crossed above signal line previous end of day
Positive Breakout (LTP > R2)
Increasing Revenue every quarter for the past 2 quarters
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Positive Breakout (LTP > R1)
High Volume, High Gain
Top Gainers
Stock with Low PE (PE < = 10)
Volume Shockers
High Volume, High Gain
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Declining profits every quarter for the past 2 quarters